What question did this study set out to answer?

The aim is to develop an inactivated vaccine using an emerging PEDV GIIc variant to enhance cross-protection.

February 6, 2026VaccinesOpen Access

A Novel Inactivated Vaccine Based on an Emerging PEDV GIIc Variant Provides Cross-Protection Against Heterologous GII Strains

View Full Paper

Ask AI

Bookmark

Authors

A novel vaccine demonstrates cross-protection against GII strains in piglets, suggesting effective outbreak control.

The aim is to develop an inactivated vaccine using an emerging PEDV GIIc variant to enhance cross-protection.
Isolated a PEDV strain from clinical samples.
Prepared an inactivated vaccine with ISA 201 VG adjuvant.
Assessed immunogenicity by measuring virus-neutralizing antibody titers and IgG levels in piglets.
Evaluated cross-protective efficacy through neutralization assays and challenges with different strains.
The isolated PEDV strain caused severe diarrhea and 100% mortality in naive piglets.
Vaccinated piglets showed strong cross-neutralizing activity against multiple strains.
In challenge studies, vaccinated piglets experienced no clinical disease, diarrhea, or viral shedding.

Xu et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark